Y. Chae

发表

Myeloid Sirtuin 6 Deficiency Causes Insulin Resistance in High-Fat Diet–Fed Mice by Eliciting Macrophage Polarization Toward an M1 Phenotype

Mi-kyung Kim, Byung-Hyun Park, E. Bae, 2017, Diabetes.

PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects.

Mi-kyung Kim, M. Son, J. G. Kim, 2011, European journal of pharmacology.

PAR-1622 is a selective peroxisome proliferator-activated receptor γ partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention

Mi-kyung Kim, M. Son, J. G. Kim, 2009, Archives of pharmacal research.

Additive effects of evogliptin in combination with pioglitazone on fasting glucose control through direct and indirect hepatic effects in diabetic mice

Mi-kyung Kim, Y. Chae, Tae-Hyoung Kim, 2018, European journal of pharmacology.

Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control

M. Son, Yc Shin, E. Yang, 2010, International Journal of Obesity.

Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists.

Hyun-Jin Kang, Jong-Wha Jung, T. Le, 2008, Journal of Medicinal Chemistry.

Prevention and treatment effect of evogliptin on hepatic steatosis in high-fat-fed animal models

Mi-kyung Kim, M. Son, E. Yang, 2017, Archives of pharmacal research.

A novel GPR119 agonist DA-1241 preserves pancreatic function via the suppression of ER stress and increased PDX1 expression.

Mi-kyung Kim, Ye-Hwang Cheong, K. Hong, 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Synthesis and Evaluation of Dapagliflozin Ester Prodrugs with Improved Hygroscopicity and Thermal Stability

Sung‐Hwa Yoon, J. H. Han, KyeongMin Kim, 2020 .

DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes.

Mi-kyung Kim, Ye-Hwang Cheong, M. Son, 2012, Life sciences.

Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.

Ye-Hwang Cheong, M. Son, Mi Kyung Kim, 2011, Bioorganic & medicinal chemistry letters.

PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.

Mi-kyung Kim, M. Son, Mi-Kyung Kim, 2008, European journal of pharmacology.

Hepatic role in an early glucose-lowering effect by a novel dipeptidyl peptidase 4 inhibitor, evogliptin, in a rodent model of type 2 diabetes.

Mi-kyung Kim, Ye-Hwang Cheong, M. Son, 2016, European journal of pharmacology.

Beneficial Effects of Evogliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, on Adiposity with Increased Ppargc1a in White Adipose Tissue in Obese Mice

Mi-kyung Kim, M. Son, Y. Chae, 2015, PloS one.

Prevention and treatment effect of evogliptin on hepatic steatosis in high-fat-fed animal models

M. Son, E. Yang, G. Ahn, 2016, Archives of Pharmacal Research.